Both in Pharmaceuticals
Phathom Pharmaceuticals vs Monopar Therapeutics
Over the past year PHAT returned −57.9% and MNPR returned −12.0%; their daily moves had a correlation of 0.14.
PHAT −57.9% MNPR −12.0%Growth of $1, one year, split-adjusted
| Metric | PHAT | MNPR |
|---|---|---|
| Price | $5.68 | $72.81 |
| Market cap | $461.7M | $488.7M |
| Today | −1.05% | +4.18% |
| 1 month | −16.2% | −8.5% |
| 6 months | −55.2% | +14.0% |
| Year to date | −65.8% | +11.5% |
| 1 year | −58.6% | −13.3% |
| Revenue growth (YoY) | +71.1% | — |
| Gross margin | 78.3% | — |
| Net margin | −16.4% | — |
| P/E (TTM) | — | — |
| Price / sales | 1.7× | — |
| Net cash | $17.6M | $134.3M |
| Dividend yield | — | — |
| Volatility (60d) | 72.0% | 52.6% |
| Short % of float | 17.5% | 23.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).